| Identification | Back Directory | [Name]
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) | [CAS]
850649-61-5 | [Synonyms]
ogL
Trajenta
Alogliptin
ALOGLIPTINA
850649-61-5
Alogliptin,98%
Unii-jhc049lo86
Trelagliptin-11
Axagliptin hydrate
Alogliptin (SYR-322)
Alogliptin(free base)
ALOGLIPTIN(ALOGLIPTINE
Trelagliptin Impurity T
Alogliptin Intermediate
Alogliptin Benzoate API
Trelagliptin Impurity 2(Alogliptin)
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)###850649-61-5
Alogliptin, 99%, effective and selective DPP-4 inhibitor
(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitri
2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile
(R)-2-[6-(3-aMino-piperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl]-benzonitrile
Benzonitrile, 2-[[6-[(3R)-3-aMino-1-piperidinyl]-3,4-dihydro-3-Methyl-2,4-dioxo-1(2H)-pyriMidinyl]Methyl]-
Alogliptin
2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile | [EINECS(EC#)]
821-899-3 | [Molecular Formula]
C18H21N5O2 | [MDL Number]
MFCD09833196 | [MOL File]
850649-61-5.mol | [Molecular Weight]
339.397 |
| Chemical Properties | Back Directory | [Melting point ]
127 - 129°C | [Boiling point ]
519.2±60.0 °C(Predicted) | [density ]
1.342 | [Fp ]
267.8℃ | [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
9.89±0.20(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Description]
Alogliptin is a dipeptidyl-peptidase IV (DPP-4) inhibitor that was
approved in Japan in 2010 for treatment of type 2 diabetes, a disease in
which insulin resistance and β-cell dysfunction lead to hyperglycemia.
As islet function is lost, the severity of insulin resistance
increases. The introduction of DPP-4 inhibitors has brought a novel
class of insulinotropic agents for the treatment options available to type
2 diabetic patients. The therapeutic potential of glucagon-like peptide 1
(GLP-1), an incretin peptide, for the treatment of type 2 diabetes was
realized in the 1990s. The insulinotropic effects of GLP-1 depend closely
on glucose concentrations providing the possibility of glucose normalization
without the risk of hypoglycemia. GLP-1 has other non-insulinotropic
physiological actions that are advantageous. It suppresses glucagon
secretion from a cells and slows gastric emptying, which contributes to
satiety and to a slower passage and reabsorption of carbohydrates. GLP-1
also contributes to satiety via a central mechanism as a neurotransmitter
with effects on the hypothalamus. | [Chemical Properties]
White Solid | [Originator]
Syrrx Inc. (now Takeda San Diego) (Japan) | [Uses]
Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4).
Antidiabetic agent. | [Definition]
ChEBI: A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of t
pe 2 diabetes. | [Brand name]
Nesina | [Clinical Use]
Dipeptidyl peptidase 4 inhibitor:
Treatment of type 2 diabetes in combination with
other therapies | [Enzyme inhibitor]
This orally available DPP-IV inhibitor (FW = 339.39 g/mol; CAS 850649-
62-6), also known as 2- ({6-[ (3R) -3-aminopiperidin-1-yl]-3-methyl-2,4-
dioxo-3,4-dihydropyrimidin-1 (2H) -yl}methyl) benzonitrile and by its trade
name Nesina? targets dipeptidyl peptidase IV, or DPP-4, thereby retarding
the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and
GIP (glucose-dependent insulinotropic peptide), both of which play a role
in regulating blood glucose levels. Alogliptin inhibition is competitive,
Ki = 24 nM. In 2013, alogliptin received FDA approval for the
treatment of type II diabetes mellitus. DPP-4 inhibitors have become
widely accepted in clinical practice because of their low risk of
hypoglycemia, favorable adverse-effect profile, and once-daily dosing. The
only reported side-effect is mild hypoglycemia, suggesting that some
individuals may benefit from a slightly lower dose. Other DPP-4 inhibitors
include sitagliptin phosphate (Januvia?) and saxagliptin (Onglyza?). DPP-4
inhibition has been associated with enhanced β-cell survival and neogenesis
in streptozotocin-treated diabetic rats (See also Streptozotocin).
Significantly, the addition of alogliptin resulted in clinically significant
reductions in HbA1c (typically from 1.4 to 1%), without increased incidence
of hypoglycemia, in type 2 diabetes patients who are inadequately
controlled by glyburide monotherapy. | [target]
DPP-4 | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Alogliptin does not undergo extensive metabolism. Two
minor metabolites were detected following administration
of an oral dose of [14C]-alogliptin, N-demethylated
alogliptin, M-I (<1% of the parent compound), and
N-acetylated alogliptin, M-II (<6% of the parent
compound). M-I is an active metabolite and is a highly
selective inhibitor of DPP-4 similar to alogliptin; M-II
does not display any inhibitory activity towards DPP-4
or other DPP-related enzymes. In vitro data indicate
that CYP2D6 and CYP3A4 contribute to the limited
metabolism of alogliptin. |
|
|